InflaRx N.V.

NASDAQ:IFRX   11:39:47 AM EDT
3.39
-0.13 (-3.69%)
Products, Regulatory

InflaRx Announces Start Of Phase III Part Of Phase II/III Clinical Trial With IFX-1 In COVID-19-Induced Pneumonia

Published: 09/14/2020 11:49 GMT
InflaRx N.V. (IFRX) - Inflarx Announces Initiation of Phase Iii Part of Phase Ii/iii Clinical Trial With Ifx-1 in Severe Covid-19 Induced Pneumonia.
Inflarx NV - German Regulatory Authority, Paul-ehrlich-institut (pei), Has Approved Phase Iii Clinical Trial in Germany.
Inflarx NV - Phase Iii Part of Phase Ii/iii Trial Plans to Enroll About 360 Early Intubated, Critically Ill Patients With Covid-19 Induced Pneumonia.